Early-Stage trial halted for new liver cancer drug pair
NCT ID NCT06320080
Summary
This was an early-stage study to test the safety and initial effectiveness of a new two-drug combination for advanced liver cancer. The treatment involved an experimental drug (TQB2223) designed to help the immune system fight cancer, given alongside another immunotherapy drug (penpulimab). The study was terminated and enrolled 22 adults with advanced liver cancer who had not received prior immunotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Affiliated Cancer Hospital of Harbin Medical University
Harbin, Heilongjiang, 150000, China
-
Hubei Provincial Tumor Hospital
Wuhan, Hubei, 430079, China
-
Hunan Provincial Tumor Hospital
Changsha, Hunan, 410031, China
Conditions
Explore the condition pages connected to this study.